Clinical Trials Brief | October 5, 2026
This week: a US indictment over counterfeit Ozempic sourced from China and sold into American distribution, FDA launching a nationwide drive to fill advisory committee seats, EMA's Board told the Biotech Act will touch about 70% of CTIS, the MHRA flagging laboratory assay interference and a fatal parenteral nutrition embolism, and the first US approval for MCT8 deficiency.
A US indictment over counterfeit Ozempic sourced from China and sold to distributors shows how fakes reach the legitimate supply chain
What changed
On September 29, 2026, the US Department of Justice announced that a federal grand jury in the Middle District of Florida had charged two Indian nationals with conspiracy and smuggling in an alleged transnational scheme to distribute counterfeit Ozempic. According to the DOJ and reporting by CBS News and Fox, the defendants allegedly obtained counterfeit product from unauthorised sources in China and sold it at deeply discounted prices to US distributors, with counterfeit packaging, package inserts, pen labels and needles. The DOJ says the scheme continued even after FDA seized some of the counterfeit Ozempic in December 2023 and issued a public warning. The charges are one count of conspiracy to commit smuggling and to defraud the United States, three counts of smuggling, and two counts of selling or holding counterfeit drugs for sale. FDA's Office of Criminal Investigations is investigating. These are allegations, and the defendants are presumed innocent unless proven guilty.
Why it matters
The case shows how counterfeits can enter regulated distribution, not just grey-market online sales: price is the lever, and distributors who accept steep discounts become the entry point. Counterfeit needles are a separate sterility risk. GLP-1 medicines are now among the most widely used drugs, so they are an obvious target. For clinical research, commercially sourced GLP-1 products are frequently used as comparators, background therapy or rescue medication in obesity, diabetes, cardiovascular and renal trials, and comparator sourcing is a known supply-chain vulnerability.
Takeaway
Sponsors and CROs that purchase commercial comparators should confirm they buy only from authorised distributors, keep chain-of-custody documentation, and check lot numbers against manufacturer and regulator alerts. In trials where participants supply their own GLP-1 medicines, a sudden unexplained loss of efficacy or unusual injection-site reactions should prompt questions about where the product came from.
Sources
This item is grounded in the US Department of Justice press release of September 29, 2026 and reporting by CBS News and Fox.
FDA launches a nationwide drive to fill advisory committee seats, after a year in which panel votes repeatedly shaped decisions
What changed
On September 30, 2026, FDA launched a nationwide recruitment effort to fill current and anticipated vacancies on its advisory committees, followed on October 1 by two Federal Register notices: one for scientific, technical and professional voting members and one for consumer representatives. FDA is seeking expertise in areas including oncology, cardiovascular medicine, neurology, genetics and medical devices. Nominations for consumer representative positions are due by November 15, 2026, and for scientific and other voting-member positions by November 30, 2026, for first consideration. According to AllSci, the consumer notice lists near-term vacancies on committees including the Science Board, the Pediatric Advisory Committee, the Blood Products Advisory Committee and the Cellular, Tissue and Gene Therapies Advisory Committee. Members can serve terms of up to four years. Acting Commissioner Kyle Diamantas said the panels provide independent expertise and rigorous scrutiny as FDA navigates complex and fast-moving science.
Why it matters
This summer showed how much advisory committees can matter: the compounding committee voted against FDA staff on peptides in July, the gene therapy committee voted 9-3 against deramiocel and 10-3 in favour of RP1, and FDA followed the panel on RP1 over its own reviewers. In his confirmation hearing the week before, FDA commissioner nominee Heidi Overton called advisory committees a critical part of FDA's processes. Who sits on these panels shapes how evidence debates turn out. Clinical Trial Vanguard notes that advisory meeting activity had contracted sharply before this recruitment push.
Takeaway
Sponsors expecting an advisory committee for 2027 filings should assume panel composition may change, and prepare presentations for members who may be new to the specific therapeutic area. Clinical researchers with relevant expertise who want to serve should note the November deadlines.
Sources
This item is grounded in FDA's announcement of September 30, 2026 as reported by The ASCO Post, AllSci and Clinical Trial Vanguard.
EMA's Board hears the Biotech Act will touch about 70% of CTIS, with first CTR changes possible from early 2028
What changed
On October 1, 2026, EMA published highlights of its September Management Board meeting. The Board was told that the trial authorisation and supervision changes in the proposed EU Biotech Act would affect about 70% of current CTIS functionality. These include faster assessments, more flexibility for major modifications to ongoing trials, more risk-proportionate authorisation, common medicinal product dossiers and simpler assessment of combined studies involving medicines, devices and in-vitro diagnostics. The Act is under discussion in the Council and Parliament, and under its ambitious timetable, first changes to the Clinical Trials Regulation could take effect in early 2028. The Board stressed delivering key CTIS functions, including accelerated timelines, as early as possible. The current platform needs immediate investment, all Biotech Act functionality will be built on a new CTIS platform with work starting in early 2027, and a detailed roadmap with resource impact will come to the Board in December 2026. CTIS has supported more than 14,000 trials since 2022, with more than 200 new applications a month. The Board also reviewed preparations for the new pharmaceutical legislation and procedures for nominating EMA's next Executive Director. Separately, CTIS's new annual safety report module went live on September 28.
Why it matters
This brief first covered EMA's Biotech Act preparations in June. The October update quantifies the change. When 70% of a system's functionality is affected, sponsors face effectively a second CTIS transition, after the difficult first one under the CTR. Because the new platform will be built alongside legislation that is still being negotiated, requirements may shift during development. For sponsors, the practical consequence is that SOPs, submission templates and training built around today's CTIS will have a limited lifespan.
Takeaway
Regulatory operations teams should plan for two parallel changes: the ASR module now, and a larger CTIS rebuild from 2027. Avoid heavy investment in CTIS-specific automation that may not survive the transition, and watch for the December 2026 roadmap.
Sources
This item is grounded in EMA's Management Board highlights published October 1, 2026.
MHRA flags falsely high digoxin results with apalutamide and enzalutamide, and a fatal embolism with unfiltered parenteral nutrition
What changed
The MHRA's September 2026 Safety Roundup, published September 29, included several items. Laboratory interference has been identified in patients taking apalutamide or enzalutamide, androgen receptor inhibitors for prostate cancer, that can cause falsely elevated digoxin results when measured by chemiluminescent microparticle immunoassay (CMIA), whether or not the patient takes digoxin. The MHRA attributes this to structural similarity with the part of the digoxin molecule the assay recognises. Unexpected results should be confirmed with an alternative assay before changing digoxin treatment, and previous results should be reviewed. A Drug Safety Update advises that all parenteral nutrition be given through a filter with a pore size no larger than 1.2 µm, with 0.2 µm good practice for lipid-free solutions, after incidents including a fatal embolism with unfiltered administration. Fluenz product information now reflects an increased risk of fainting immediately after the nasal spray. The roundup also lists the UK DHPC suspending Avacopan Vifor for new patients.
Why it matters
Assay interference is a quiet risk to trial data integrity. A falsely high digoxin level can lead to unnecessary dose reductions or discontinuation, and in a clinical trial it can be recorded as a laboratory abnormality or even an adverse event that never happened. The same issue arises with tiratricol, approved in the US this week, which can falsely elevate T3 results. The parenteral nutrition advice is directly relevant to home-based and decentralised care, where PN is increasingly given by patients or carers.
Takeaway
Central laboratories and medical monitors should keep a list of known drug-assay interferences for investigational and concomitant drugs and check which assay platforms trial labs use. In prostate cancer trials with androgen receptor inhibitors, flag digoxin results from CMIA methods for confirmation before they drive safety decisions.
Sources
This item is grounded in the MHRA Safety Roundup for September 2026, published September 29.
FDA approves tiratricol, the first US treatment for MCT8 deficiency, 19 months after the EU
What changed
On September 28, 2026, FDA approved Emcitate (tiratricol, Egetis Therapeutics), tablets for oral suspension, to treat peripheral thyrotoxicosis in adults and children with MCT8 deficiency (Allan-Herndon-Dudley syndrome), an X-linked disorder in which thyroid hormone cannot be transported properly into cells, including into the brain. FDA explained that tiratricol can enter cells without relying on the defective transporter, lowering elevated blood thyroid hormone levels. It is the first FDA-approved therapy for the condition. The drug received Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations and Priority Review, and was approved on its PDUFA date. The European Commission approved it in February 2025 as the first EU treatment for the disease. According to Contemporary Pediatrics, the indication covers peripheral thyrotoxicosis, not the neurodevelopmental features of the disease. Epocrates notes that tiratricol may interfere with T3 laboratory tests and produce falsely elevated results. Drug Discovery News reports fewer than 600 known patients worldwide.
Why it matters
This is an ultra-rare disease approval with a carefully bounded indication. The drug treats the measurable peripheral consequence of the transporter defect (excess thyroid hormone in the blood, with its cardiac and metabolic effects), while the neurodevelopmental impact remains unaddressed by the label. That pattern matters for rare-disease trial design: approval on a biochemical and systemic endpoint is achievable, but the claim follows exactly what the evidence measured. The 19-month gap between EU and US approval is also unusual, given that EU approvals often come later than US ones.
Takeaway
For ultra-rare disease programmes, align indication wording with the endpoint the trials can actually show, and plan separate evidence generation for harder outcomes such as neurodevelopment. Trial teams should also note the T3 assay interference when interpreting thyroid tests in participants receiving tiratricol.
Sources
This item is grounded in FDA's announcement of September 28, 2026, Egetis Therapeutics' press release, and reporting by Contemporary Pediatrics, epocrates and Drug Discovery News.